TAP’s new five year partnership with EPSRC will mean the further development and testing of its CompacT CellBase system for culturing clinically applicable stem cells in a Good Manufacturing Practice (GMP) environment.
Additionally, the funding is expected to allow TAP to begin new research with the centre to develop ambr, TAP’s advanced microscale bioreactor that mimics the characteristics of classical bioreactors. The project will enable the centre to explore the use of alternative technology platforms to ensure high quality stem cell therapies are manufactured both rapidly and cost-effectively.
The new collaboration is a continuation of the work TAP began as part of the remedi (regenerative medicine) EPSRC Grand Challenge consortium in 2005, and has contributed to remedi achieving three automated cell culture, including production in a CompacT CellBase of a clinical grade neuronal stem cell line.
David Newble, CEO of TAP, said: We are delighted our collaboration with the EPSRC Centre for Innovative Manufacturing in Regenerative Medicine will continue to be funded and is a great endorsement of the success we have all achieved with the remedi consortium. Utilising and developing TAP’s innovative technology is firmly at the heart of this partnership and sends a clear signal that TAP is leading the way in regenerative medicine and playing a vital role in making affordable new stem cell therapies a reality.”